Department of Pharmacology and Toxicology, American University of Beirut Faculty of Medicine, 1107-2020 Beirut, Lebanon.
The Cardiovascular, Renal, and Metabolic Diseases Research Center of Excellence, American University of Beirut Medical Center, Riad El-Solh, 1107-2020 Beirut, Lebanon.
Front Biosci (Landmark Ed). 2024 Jan 12;29(1):8. doi: 10.31083/j.fbl2901008.
Kidney damage in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can occur even in patients with no underlying kidney disease. Signs of kidney problems can progress to a state that demands dialysis and hampering recovery. Although not without controversy, emerging evidence implicates direct infectivity of SARS-CoV-2 in the kidney. At the early stage of the pandemic, consideration was mainly on the well-recognized angiotensin-converting enzyme 2 (ACE2) receptor as being the site for viral interaction and subsequent cellular internalization. Despite the abundance of ACE2 receptors in the kidneys, researchers have expanded beyond ACE2 and identified novel viral entry pathways that could be advantageously explored as therapeutic targets. This review presents the potential involvement of toll-like receptor 4 (TLR-4), kidney injury molecule-1/T cell immunoglobulin mucin domain 1 (KIM-1/TIM-1), and cluster of differentiation 147 (CD147) in SARS-CoV-2-associated renal damage. In this context, we address the unresolved issues surrounding SARS-CoV-2 renal infectivity.
严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 可导致无基础肾脏疾病患者发生肾脏损害。肾脏问题的迹象可进展至需要透析的严重程度,从而阻碍康复。虽然存在争议,但新出现的证据表明 SARS-CoV-2 具有直接感染肾脏的能力。在大流行早期,主要考虑的是众所周知的血管紧张素转换酶 2 (ACE2) 受体作为病毒相互作用和随后细胞内化的部位。尽管肾脏中 ACE2 受体丰富,但研究人员已超越 ACE2 并确定了新的病毒进入途径,这些途径可作为有前途的治疗靶点进行探索。本综述介绍了 Toll 样受体 4 (TLR-4)、肾损伤分子-1/T 细胞免疫球蛋白黏蛋白结构域 1 (KIM-1/TIM-1) 和分化群 147 (CD147) 在 SARS-CoV-2 相关肾损伤中的潜在作用。在这种情况下,我们解决了围绕 SARS-CoV-2 肾感染性的未解决问题。